LabTech launches MicroStreak in US
Wednesday, 11 June, 2008
Adelaide-based diagnostics company LabTech Systems (ASX: LBT) has launched its MicroStreak technology in the US.
The company held a launch for the product, which has been named PREVI Isola by licensees bioMerieux, at the American Society of Microbiology meeting held in Boston this week.
MicroStreak is a new method of microbiology processing, automating the streaking of agar plates to test samples. The technology was already launched in Europe in April.
LabTech has earned $4.9 million in licence fees to date.
For a full report on the MicroStreak, see the July/August edition of Australian Life Scientist.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
